Non-small cell lung cancer
Conditions
Interventions
Gold Standard:Pathological diagnosis tumor samples
cell 
lung 
cancer 
10 
driver 
using 
samples
Sponsors
Beijing Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 90 Years
Inclusion criteria
Inclusion criteria: If it satisfies 1 and any of 2-6 can be included in the group. 1. Patients who can obtain biopsy or other cytological specimens of sputum, and use this specimen for gene change detection at the same time. The detection reagents must use the reagents approved by the authority, including arms method and ngs method. For ALK gene and other fusion gene detection methods, including: Ventana ALK (d5f3) immunohistochemical detection, fish or RT-PCR method; 2. Patients with NSCLC in stage IIIB-IV; 3. NSCLC patients with recurrence or metastasis were not confirmed by targeted drug therapy after surgery; 4. Patients with advanced NSCLC treated with EGFR small molecule inhibitors of the first generation to the third generation and alk inhibitors from the first generation to the third generation; 5. Other targeted drugs are used to treat patients with drug resistance; 6. Normal control group, no tumor population, no tumor population after follow-up.
Exclusion criteria
Exclusion criteria: 1. Patients who failed to obtain tumor tissue and cytological specimens for definite pathological diagnosis; 2. The patients who did not obtain the results of non-small cell lung cancer driver gene test were not found; 3. Diagnosis of non-small cell lung cancer patients with respiratory infection; 4. Sputum samples were obtained and diagnosed as unqualified sputum samples by cytology and pathology. Unqualified sputum samples were defined as no epithelial cells or phagocytes in sputum smears under microscope (according to the results of previous studies, the sensitivity of driving gene change detection of such samples was 0).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Driver gene mutation results; | — |
Secondary
| Measure | Time frame |
|---|---|
| The positive rate and negative rate of driver gene between natural sputum group and induced sputum group. The sensitivity, specificity, PPV, NPV and concordance of sputum sample compared with tumor sample.;PFS and OS of patients after targeted therapy; | — |
Countries
China
Contacts
Public ContactZheng Wang
Beijing Hospital
Outcome results
None listed